RU2000117580A - NEW CONNECTIONS - Google Patents
NEW CONNECTIONSInfo
- Publication number
- RU2000117580A RU2000117580A RU2000117580/04A RU2000117580A RU2000117580A RU 2000117580 A RU2000117580 A RU 2000117580A RU 2000117580/04 A RU2000117580/04 A RU 2000117580/04A RU 2000117580 A RU2000117580 A RU 2000117580A RU 2000117580 A RU2000117580 A RU 2000117580A
- Authority
- RU
- Russia
- Prior art keywords
- tricyclo
- acetamide
- decane
- methylphenyl
- group
- Prior art date
Links
- -1 cyano, carboxyl Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 230000000240 adjuvant Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- OSLSOHDGPDZQPH-UHFFFAOYSA-N 2-(1-adamantyl)-N-(1-methylindol-5-yl)acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=C2N(C)C=CC2=C1 OSLSOHDGPDZQPH-UHFFFAOYSA-N 0.000 claims 1
- BIGMDHWABCUPQT-UHFFFAOYSA-N 2-(1-adamantyl)-N-(1H-indazol-5-yl)acetamide Chemical compound C1=C2NN=CC2=CC(NC(CC23CC4CC(CC(C4)C2)C3)=O)=C1 BIGMDHWABCUPQT-UHFFFAOYSA-N 0.000 claims 1
- DLCLMRYRNYXSQN-UHFFFAOYSA-N 2-(1-adamantyl)-N-(1H-indazol-6-yl)acetamide Chemical compound C1=C2C=NNC2=CC(NC(CC23CC4CC(CC(C4)C2)C3)=O)=C1 DLCLMRYRNYXSQN-UHFFFAOYSA-N 0.000 claims 1
- SVTLGMPTRHCTLJ-UHFFFAOYSA-N 2-(1-adamantyl)-N-(1H-indol-4-yl)acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=C1C=CN2 SVTLGMPTRHCTLJ-UHFFFAOYSA-N 0.000 claims 1
- UXJWWSMUVCSTEW-UHFFFAOYSA-N 2-(1-adamantyl)-N-(1H-indol-5-yl)acetamide Chemical compound C1=C2NC=CC2=CC(NC(CC23CC4CC(CC(C4)C2)C3)=O)=C1 UXJWWSMUVCSTEW-UHFFFAOYSA-N 0.000 claims 1
- ZBAULNAVBAJLNJ-UHFFFAOYSA-N 2-(1-adamantyl)-N-(2,3-dimethyl-1H-indol-5-yl)acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=C2NC(C)=C(C)C2=C1 ZBAULNAVBAJLNJ-UHFFFAOYSA-N 0.000 claims 1
- PHBGFBNHBDBYET-UHFFFAOYSA-N 2-(1-adamantyl)-N-(2,3-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CC23CC4CC(CC(C4)C2)C3)=C1C PHBGFBNHBDBYET-UHFFFAOYSA-N 0.000 claims 1
- XASVLMPNSMNJFZ-UHFFFAOYSA-N 2-(1-adamantyl)-N-(2,4,5-trimethylphenyl)acetamide Chemical compound C1=C(C)C(C)=CC(C)=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 XASVLMPNSMNJFZ-UHFFFAOYSA-N 0.000 claims 1
- QBHNWZPYQIPYNH-UHFFFAOYSA-N 2-(1-adamantyl)-N-(2,4,6-trimethylphenyl)acetamide Chemical compound CC1=CC(C)=CC(C)=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 QBHNWZPYQIPYNH-UHFFFAOYSA-N 0.000 claims 1
- LCAIOQWPNYFIAX-UHFFFAOYSA-N 2-(1-adamantyl)-N-(2-chloro-4-hydroxyphenyl)acetamide Chemical compound ClC1=CC(O)=CC=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 LCAIOQWPNYFIAX-UHFFFAOYSA-N 0.000 claims 1
- VXYIAZHMWAMZAO-UHFFFAOYSA-N 2-(1-adamantyl)-N-(2-chloro-5-hydroxyphenyl)acetamide Chemical compound OC1=CC=C(Cl)C(NC(=O)CC23CC4CC(CC(C4)C2)C3)=C1 VXYIAZHMWAMZAO-UHFFFAOYSA-N 0.000 claims 1
- KTFKTOQYWBSSGI-UHFFFAOYSA-N 2-(1-adamantyl)-N-(2-chloro-5-methoxyphenyl)acetamide Chemical compound COC1=CC=C(Cl)C(NC(=O)CC23CC4CC(CC(C4)C2)C3)=C1 KTFKTOQYWBSSGI-UHFFFAOYSA-N 0.000 claims 1
- BYJXYKKUYFQBBS-UHFFFAOYSA-N 2-(1-adamantyl)-N-(2-chlorophenyl)acetamide Chemical compound ClC1=CC=CC=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 BYJXYKKUYFQBBS-UHFFFAOYSA-N 0.000 claims 1
- UALQSPNYZDCJEL-UHFFFAOYSA-N 2-(1-adamantyl)-N-(3,5-dihydroxy-2-methylphenyl)acetamide Chemical compound CC1=C(O)C=C(O)C=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 UALQSPNYZDCJEL-UHFFFAOYSA-N 0.000 claims 1
- FABADLZKBTWKFK-UHFFFAOYSA-N 2-(1-adamantyl)-N-(3,5-dihydroxyphenyl)acetamide Chemical compound OC1=CC(O)=CC(NC(=O)CC23CC4CC(CC(C4)C2)C3)=C1 FABADLZKBTWKFK-UHFFFAOYSA-N 0.000 claims 1
- YUJRCFBSMIGYOL-UHFFFAOYSA-N 2-(1-adamantyl)-N-(3,5-dimethoxy-2-methylphenyl)acetamide Chemical compound COC1=CC(OC)=CC(NC(=O)CC23CC4CC(CC(C4)C2)C3)=C1C YUJRCFBSMIGYOL-UHFFFAOYSA-N 0.000 claims 1
- ITZZJGGGGVJVMG-UHFFFAOYSA-N 2-(1-adamantyl)-N-(3,5-dimethoxyphenyl)acetamide Chemical compound COC1=CC(OC)=CC(NC(=O)CC23CC4CC(CC(C4)C2)C3)=C1 ITZZJGGGGVJVMG-UHFFFAOYSA-N 0.000 claims 1
- JBPWCMHRHHGKNO-UHFFFAOYSA-N 2-(1-adamantyl)-N-(3-hydroxy-2-methylphenyl)acetamide Chemical compound CC1=C(O)C=CC=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 JBPWCMHRHHGKNO-UHFFFAOYSA-N 0.000 claims 1
- HMFZJPXGIJLMTJ-UHFFFAOYSA-N 2-(1-adamantyl)-N-(3-methoxy-2-methylphenyl)acetamide Chemical compound COC1=CC=CC(NC(=O)CC23CC4CC(CC(C4)C2)C3)=C1C HMFZJPXGIJLMTJ-UHFFFAOYSA-N 0.000 claims 1
- HPUFAJMLWKNPAX-UHFFFAOYSA-N 2-(1-adamantyl)-N-(4-hydroxy-2-methylphenyl)acetamide Chemical compound CC1=CC(O)=CC=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 HPUFAJMLWKNPAX-UHFFFAOYSA-N 0.000 claims 1
- XNZRWYXINRNDIA-UHFFFAOYSA-N 2-(1-adamantyl)-N-(4-methoxy-2-methylphenyl)acetamide Chemical compound CC1=CC(OC)=CC=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 XNZRWYXINRNDIA-UHFFFAOYSA-N 0.000 claims 1
- ZSUYVGHSBYLZLT-UHFFFAOYSA-N 2-(1-adamantyl)-N-(5-hydroxy-2-methylphenyl)acetamide Chemical compound CC1=CC=C(O)C=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 ZSUYVGHSBYLZLT-UHFFFAOYSA-N 0.000 claims 1
- SLETUOPOZZOYNK-UHFFFAOYSA-N 2-(1-adamantyl)-N-(5-methoxy-2-methyl-3-nitrophenyl)acetamide Chemical compound [O-][N+](=O)C1=CC(OC)=CC(NC(=O)CC23CC4CC(CC(C4)C2)C3)=C1C SLETUOPOZZOYNK-UHFFFAOYSA-N 0.000 claims 1
- APLGQRPVXWWNAW-UHFFFAOYSA-N 2-(1-adamantyl)-N-(5-methoxy-2-methylphenyl)acetamide Chemical compound COC1=CC=C(C)C(NC(=O)CC23CC4CC(CC(C4)C2)C3)=C1 APLGQRPVXWWNAW-UHFFFAOYSA-N 0.000 claims 1
- PDSHVDDKOVCTTR-UHFFFAOYSA-N 2-(1-adamantyl)-N-[3,5-bis(3-aminopropoxy)phenyl]acetamide Chemical compound NCCCOC1=CC(OCCCN)=CC(NC(=O)CC23CC4CC(CC(C4)C2)C3)=C1 PDSHVDDKOVCTTR-UHFFFAOYSA-N 0.000 claims 1
- VMZUWWGMBTWPST-UHFFFAOYSA-N 2-(1-adamantyl)-N-[3-(hydroxymethyl)-2-methylphenyl]acetamide Chemical compound CC1=C(CO)C=CC=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 VMZUWWGMBTWPST-UHFFFAOYSA-N 0.000 claims 1
- ZDNRWKDLKLHMCN-UHFFFAOYSA-N 2-(1-adamantyl)-N-[5-(3-aminopropoxy)-2-methylphenyl]acetamide;hydrochloride Chemical compound Cl.CC1=CC=C(OCCCN)C=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 ZDNRWKDLKLHMCN-UHFFFAOYSA-N 0.000 claims 1
- RVKUXEVGPXVNKU-UHFFFAOYSA-N 2-(1-adamantyl)-N-[5-(hydroxymethyl)-2-methylphenyl]acetamide Chemical compound CC1=CC=C(CO)C=C1NC(=O)CC1(C2)CC(C3)CC2CC3C1 RVKUXEVGPXVNKU-UHFFFAOYSA-N 0.000 claims 1
- XRWXZXBEBCYUBC-UHFFFAOYSA-N 2-(1-adamantyl)-N-[5-(methoxymethyl)-2-methylphenyl]acetamide Chemical compound COCC1=CC=C(C)C(NC(=O)CC23CC4CC(CC(C4)C2)C3)=C1 XRWXZXBEBCYUBC-UHFFFAOYSA-N 0.000 claims 1
- SDRSRSVAUNFSNJ-UHFFFAOYSA-N 2-[5-[[2-(1-adamantyl)acetyl]amino]indol-1-yl]acetic acid Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=C2N(CC(=O)O)C=CC2=C1 SDRSRSVAUNFSNJ-UHFFFAOYSA-N 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N Tert-Butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000001506 immunosuppresive Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
Claims (13)
где А обозначает группу CH2 или атом кислорода;
В обозначает атом водорода или галогена;
D обозначает группу CH2, OCH2, NHCH2 или CH2CH2;
R обозначает фенильную, бензотиазолильную, индолильную, индазолильную, пуринильную, пиридильную, пиримидинильную или тиофенильную группу, каждая из которой может быть необязательно замещена одним или большим числом заместителей, выбранных, независимо друг от друга, из атома галогена или циано, карбоксильной, гидроксильной, нитро, галоген-С1-С6-алкильной, -N(R1)-C(= C)-R2, -C(O)NR3R4, -NR5R6, С3-С8-циклоалкильной, 3-8-членной гетероциклильной, С3-С8-циклоалкилокси, C1-С6-алкилкарбонильной, фенокси, бензильной, C1-С6-алкилтио, фенилтио, C1-С6-алкоксикарбонильной, C1-С6-алкилсульфинильной или C1-С6-алкилсульфонильной группы, или C1-С6-алкильной или C1-С6-алкокси группы, необязательно замещенной одним или более заместителями, выбранными, независимо друг от друга, из атома галогена или амино, карбоксильной, гидроксильной, C1-С6-алкокси, (ди)C1-С6-алкиламино, C1-С6-алкоксикарбонильной, имидазолильной, морфолинильной, пиперидинильной или пирролидинильной групп;
R1 обозначает атом водорода или C1-С6-алкильную или С3-С8-циклоалкильную группу;
R2 обозначает C1-С6-алкильную или С3-С8-циклоалкильную группы; и
R3, R4, R5 и R6 обозначают, каждый, независимо друг от друга, атом водорода или C1-С6-алкильную или С3-С8-циклоалкильную группу;
при условии, что
(i) когда А обозначает СН2, В обозначает Н и D обозначает СН2, то R не обозначает фенильную, орто-карбоксифенильную, орто-нитрофенильную, ортоаминофенильную, орто-(диметиламиноэтил)фенильную, метилфенильную или пара-феноксифенильную группу, и
(ii) когда А обозначает CH2, В обозначает Br и D обозначает СН2, то R не обозначает орто-карбоксифенильную группу, и
(iii) когда А обозначает СН2, В обозначает Н и D обозначает CH2CH2, то R не обозначает фенильную группу, и
(iv) когда А обозначает СН2, D обозначает СН2 или CH2CH2 и R обозначает замещенную фенильную группу, присутствующие заместитель или заместители не включают в орто-положении C1-С6-алкокси группу, замещенную амино, (ди)C1-С6-алкиламино, имидазолильной, морфолинильной, пиперидинильной или пирролидинильной группой;
или к его фармацевтически приемлемой соли или сольвату.1. The compound of the General formula
where a denotes a group of CH 2 or an oxygen atom;
B represents a hydrogen or halogen atom;
D represents a CH 2 , OCH 2 , NHCH 2 or CH 2 CH 2 group;
R denotes a phenyl, benzothiazolyl, indolyl, indazolyl, purinyl, pyridyl, pyrimidinyl or thiophenyl group, each of which may be optionally substituted by one or more substituents selected independently from each other from a halogen atom or cyano, carboxyl, hydroxyl, nitro , halogen-C 1 -C 6 -alkyl, -N (R 1 ) -C (= C) -R 2 , -C (O) NR 3 R 4 , -NR 5 R 6 , C 3 -C 8 -cycloalkyl , 3-8 membered heterocyclyl, C 3 -C 8 -tsikloalkiloksi, C 1 -C 6 alkylcarbonyl, phenoxy, benzyl, C 1 -C 6 -alkylthio, phenylthio, C 1 -C 6 -alkok ikarbonilnoy, C 1 -C 6 -alkilsulfinilnoy or C 1 -C 6 -alkilsulfonilnoy groups or C 1 -C 6 alkyl or C 1 -C 6 -alkoxy group optionally substituted by one or more substituents independently selected from each other , from a halogen atom or amino, carboxyl, hydroxyl, C 1 -C 6 alkoxy, (di) C 1 -C 6 alkylamino, C 1 -C 6 alkoxycarbonyl, imidazolyl, morpholinyl, piperidinyl or pyrrolidinyl groups;
R 1 denotes a hydrogen atom or a C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl group;
R 2 represents C 1 -C 6 -alkyl or C 3 -C 8 -cycloalkyl groups; and
R 3 , R 4 , R 5 and R 6 denote, each independently of one another, a hydrogen atom or a C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl group;
provided that
(i) when A is CH 2 , B is H and D is CH 2 , then R does not mean a phenyl, ortho-carboxyphenyl, ortho-nitrophenyl, ortho-aminophenyl, ortho- (dimethylaminoethyl) phenyl, methylphenyl or para-phenoxyphenyl group, and
(ii) when A is CH 2 , B is Br, and D is CH 2 , then R does not mean an ortho-carboxyphenyl group, and
(iii) when A is CH 2 , B is H and D is CH 2 CH 2 , then R does not represent a phenyl group, and
(iv) when A is CH 2 , D is CH 2 or CH 2 CH 2 and R is a substituted phenyl group, the substituent or substituents present do not include in the ortho position a C 1 -C 6 alkoxy group, a substituted amino, (di) C 1 -C 6 -alkylamino, imidazolyl, morpholinyl, piperidinyl or pyrrolidinyl group;
or its pharmaceutically acceptable salt or solvate.
N-(2-метил-6-бензатиазолил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(3-(3-(аминопропилокси)-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
N-(2-хлорфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(2,4,5-триметилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(5-метокси-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(2,3-диметилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(5-индолил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(2,3-диметил-5-индолил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-[5-(3-N, N-диметиламинопропокси)-2-метилфенил] -трицикло[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
N-(5-индазолил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(6-индазолил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(5-гидрокси-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(1Н-индол-4-ил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
4-метил-3-[[1-оксо-2-(трицикло[3.3.1.13,7] дек-1-ил)этил] -амино] феноксиуксусной кислоты гидрохлоридная соль,
N-(1-метил-1Н-индол-5-ил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(1-(N, N-диметиламино)этил-1Н-индо-5-ил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
5-[[1-оксо-2-(трицикло[3.3.1.13,7] дек-1-ил)этил] амино] -1Н-индол-1-уксусной кислоты 1,1-диметилэтиловый эфир,
N-(3-(2-хлорпиридил))-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(3-N, N-диметиламино)метил-1Н-индо-5-ил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(4-метокси-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(2-хлор-5-метоксифенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(4-гидрокси-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(3-гидроксиметил-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(5-метокси-2-метил-3-нитрофенил)-трицикло[3.3.1.13,7] -декан-1-ацетамид,
N-(5-гидроксиметил-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(3-гидрокси-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(2-метил-5-(1-пирролидинметил)фенил)-трицикло[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
N-(2-хлор-5-гидроксифенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(2-хлор-4-гидроксифенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(2-метил-3-(2-(1-пирролидино)этилокси)фенил)-трицикло-[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
N-(5-метоксиметил-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(2-метил-3-(2-(1-морфолино)этилокси)фенил)-трицикло[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
N-(2-метил-3-(2-(1-пиперидино)этилокси)фенил)-трицикло[3.3,1.13,7] декан-1-ацетамида гидрохлорид,
N-(2-метил-5-(1-морфолинометил)фенил)-трицикло[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
N-(5-(3-(2-N, N-диметиламиноэтил)индолил))-трицикло[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
Метил 4-метил-3-[[1-оксо-2-(трицикло[3.3.1.13,7] дек-1-ил)этил] амино] тиофен-2-карбоксилат,
N-(3-метокси-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(2-метил-3-(2-(1-имидазоло)этилокси)фенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(2,4,6-триметилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(5-(3-аминопропилокси)-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
N-(5-(3-(N-метиламино)пропилокси)-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
N6-(трицикло[3.3.1.13,7] декан-1-ацетил)-аденин,
N-(3,5-диметокси-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(3-(3-(N-метиламино)пропилокси)-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
N-(5-(3-(N, N-диметиламино)пропилокси)-2-метилфенил)-трицикло[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
N-(5-метокси-2-метифенил)-трицикло[3.3.1.13,7] деканилокси-1-ацетамид,
N-(5-метокси-2-метилфенил)-(3-бром-трицикло[3.3.1.13,7] -декан)-1-ацетамид,
N-(3-метокси-2-метилфенил)-(2-окса-трицикло[3.3.1.13,7] -декан)-1-ацетамид,
N-(5-метокси-2-метилфенил)-2-(трицикло[3.3.1.13,7] декан-1-амино)ацетамид,
N-(3,5-диметоксифенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(3,5-дигидроксифенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(3,5-диметоксифенил)-трицикло[3.3.1.13,7] деканилокси-1-ацетамид,
N-(3,5-бис-(3-аминопропилокси)фенил)-трицикло[3.3.1.13,7] декан-1-ацетамид,
N-(2,4,5-триметилфенил)-трицикло[3.3.1.13,7] деканилокси-1-ацетамид,
N-(5-гидрокси-2-метилфенил)-трицикло[3.3.1.13,7] деканилокси-1-ацетамид,
N-(5-(2-(N-метиламино)этилокси)-2-метилфенил)-трицикло-[3.3.1.13,7] декан-1-ацетамида гидрохлорид,
N-(5-(2-(N-метиламино)этилокси)-2-метилфенил)-трицикло-[3.3.1.13,7] деканилокси-1-ацетамид,
N-(5-(3-(N-метиламино)пропилокси)-2-метилфенил)-трицикло[3.3.1.13,7] деканилокси-1-ацетамид и
N-(3,5-дигидрокси-2-метилфенил)-трицикло[3.3.1.13,7] -декан-1-ацетамид.6. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, which are:
N- (2-methyl-6-benzathiazolyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (3- (3- (aminopropyl) -2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N- (2-chlorophenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (2,4,5-trimethylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (5-methoxy-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (2,3-dimethylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (5-indolyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (2,3-dimethyl-5-indolyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- [5- (3-N, N-dimethylaminopropoxy) -2-methylphenyl] -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N- (5-indazolyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (6-indazolyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (5-hydroxy-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (1H-indol-4-yl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
4-methyl-3 - [[1-oxo-2- (tricyclo [3.3.1.1 3,7 ] dec-1-yl) ethyl] amino] phenoxyacetic acid hydrochloride salt,
N- (1-methyl-1H-indol-5-yl) -tricyclo [3.3.1.1 3,7 ] decan-1-acetamide,
N- (1- (N, N-dimethylamino) ethyl-1H-indo-5-yl) -tricyclo [3.3.1.1 3,7 ] decan-1-acetamide,
5 - [[1-oxo-2- (tricyclo [3.3.1.1 3,7 ] dec-1-yl) ethyl] amino] -1H-indole-1-acetic acid 1,1-dimethyl ethyl ester,
N- (3- (2-chloropyridyl)) - tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (3-N, N-dimethylamino) methyl-1H-indo-5-yl) tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (4-methoxy-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (2-chloro-5-methoxyphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (4-hydroxy-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (3-hydroxymethyl-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (5-methoxy-2-methyl-3-nitrophenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (5-hydroxymethyl-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (3-hydroxy-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (2-methyl-5- (1-pyrrolidinmethyl) phenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N- (2-chloro-5-hydroxyphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (2-chloro-4-hydroxyphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (2-methyl-3- (2- (1-pyrrolidino) ethyloxy) phenyl) -tricyclo- [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N- (5-methoxymethyl-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (2-methyl-3- (2- (1-morpholino) ethyloxy) phenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N- (2-methyl-3- (2- (1-piperidino) ethyloxy) phenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N- (2-methyl-5- (1-morpholinomethyl) phenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N- (5- (3- (2-N, N-dimethylaminoethyl) indolyl)) - tricyclo [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
Methyl 4-methyl-3 - [[1-oxo-2- (tricyclo [3.3.1.1 3,7 ] dec-1-yl) ethyl] amino] thiophene-2-carboxylate,
N- (3-methoxy-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (2-methyl-3- (2- (1-imidazolo) ethyloxy) phenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (2,4,6-trimethylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (5- (3-aminopropyloxy) -2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N- (5- (3- (N-methylamino) propyloxy) -2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N6- (tricyclo [3.3.1.1 3,7 ] decane-1-acetyl) -adenine,
N- (3,5-dimethoxy-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (3- (3- (N-methylamino) propyloxy) -2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N- (5- (3- (N, N-dimethylamino) propyloxy) -2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N- (5-methoxy-2-methiphenyl) -tricyclo [3.3.1.1 3,7 ] decanyloxy-1-acetamide,
N- (5-methoxy-2-methylphenyl) - (3-bromo-tricyclo [3.3.1.1 3,7 ] -decan) -1-acetamide,
N- (3-methoxy-2-methylphenyl) - (2-oxa-tricyclo [3.3.1.1 3,7 ] -decan) -1-acetamide,
N- (5-methoxy-2-methylphenyl) -2- (tricyclo [3.3.1.1 3,7 ] decane-1-amino) acetamide,
N- (3,5-dimethoxyphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (3,5-dihydroxyphenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (3,5-dimethoxyphenyl) -tricyclo [3.3.1.1 3,7 ] decanyloxy-1-acetamide,
N- (3,5-bis- (3-aminopropyloxy) phenyl) -tricyclo [3.3.1.1 3,7 ] decane-1-acetamide,
N- (2,4,5-trimethylphenyl) -tricyclo [3.3.1.1 3,7 ] decanyloxy-1-acetamide,
N- (5-hydroxy-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decanyloxy-1-acetamide,
N- (5- (2- (N-methylamino) ethyloxy) -2-methylphenyl) -tricyclo- [3.3.1.1 3,7 ] decane-1-acetamide hydrochloride,
N- (5- (2- (N-methylamino) ethyloxy) -2-methylphenyl) -tricyclo- [3.3.1.1 3,7 ] decanyloxy-1-acetamide,
N- (5- (3- (N-methylamino) propyloxy) -2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decanyloxy-1-acetamide and
N- (3,5-dihydroxy-2-methylphenyl) -tricyclo [3.3.1.1 3,7 ] decan-1-acetamide.
где L обозначает удаляемую группу и А, В и D определены в формуле (I), с соединением общей формулы (III) -R-NH2, где R определен в формуле (I); и необязательно с образованием фармацевтически приемлемой соли или сольвата.7. A method of obtaining a compound of formula (I) according to claim 1, which comprises reacting a compound of the general formula
where L denotes a leaving group and A, B and D are defined in formula (I), with a compound of general formula (III) —R — NH 2 , where R is defined in formula (I); and optionally to form a pharmaceutically acceptable salt or solvate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9704545-4 | 1997-12-05 | ||
SE9704545A SE9704545D0 (en) | 1997-12-05 | 1997-12-05 | Novel compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000117580A true RU2000117580A (en) | 2002-05-27 |
RU2197477C2 RU2197477C2 (en) | 2003-01-27 |
Family
ID=20409282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000117580/04A RU2197477C2 (en) | 1997-12-05 | 1998-12-01 | Derivatives of adamantane, method of their synthesis, pharmaceutical composition based on thereof, method of its preparing and method of effect on immune suppression |
Country Status (25)
Country | Link |
---|---|
US (1) | US6242470B1 (en) |
EP (1) | EP1036058B1 (en) |
JP (1) | JP2001525391A (en) |
KR (1) | KR20010032708A (en) |
CN (1) | CN1280560A (en) |
AT (1) | ATE234274T1 (en) |
AU (1) | AU746716B2 (en) |
BR (1) | BR9813368A (en) |
CA (1) | CA2312889A1 (en) |
DE (1) | DE69812159T2 (en) |
DK (1) | DK1036058T3 (en) |
EE (1) | EE200000320A (en) |
ES (1) | ES2195433T3 (en) |
HK (1) | HK1028594A1 (en) |
HU (1) | HUP0100431A3 (en) |
IL (1) | IL136503A0 (en) |
NO (1) | NO20002785L (en) |
NZ (1) | NZ504375A (en) |
PL (1) | PL340890A1 (en) |
PT (1) | PT1036058E (en) |
RU (1) | RU2197477C2 (en) |
SE (1) | SE9704545D0 (en) |
SK (1) | SK8412000A3 (en) |
TR (1) | TR200001558T2 (en) |
WO (1) | WO1999029660A1 (en) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ514477A (en) * | 1999-04-09 | 2003-04-29 | Astrazeneca Ab | Adamantane derivatives |
SE9904505D0 (en) * | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
SE9904738D0 (en) * | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
EP1741722A3 (en) * | 2000-10-21 | 2007-03-14 | AstraZeneca AB | Polymorphisms in the human P2X7 gene |
JP2002330787A (en) * | 2000-10-21 | 2002-11-19 | Astrazeneca Ab | Chemical substance |
HUP0400708A3 (en) * | 2000-12-07 | 2007-10-29 | Cv Therapeutics | Substituted 1,3,5-triazine and pyrimidine derivatives, their use and pharmaceutical compositions containing them |
US6995285B2 (en) * | 2000-12-07 | 2006-02-07 | Cv Therapeutics, Inc. | ABCA-1 elevating compounds |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
GB0121941D0 (en) | 2001-09-11 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
WO2003042190A1 (en) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
PA8557501A1 (en) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | BENZAMIDA, HETEROARILAMIDA AND INVESTED AMIDAS |
SE0103836D0 (en) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
SE0200920D0 (en) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
JP2005532280A (en) | 2002-04-03 | 2005-10-27 | アストラゼネカ アクチボラグ | Compound |
CA2501547A1 (en) * | 2002-10-15 | 2004-04-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
PA8591801A1 (en) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | BENZAMID INHIBITORS OF THE P2X7 RECEIVER. |
US7071223B1 (en) * | 2002-12-31 | 2006-07-04 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
SE0300480D0 (en) * | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
BRPI0410349A (en) * | 2003-05-12 | 2006-05-30 | Pfizer Prod Inc | p2x7 receptor benzamide inhibitors |
WO2004105796A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
TW200507829A (en) * | 2003-05-29 | 2005-03-01 | Astrazeneca Ab | New combination |
US20070010497A1 (en) * | 2003-05-29 | 2007-01-11 | Nigel Boughton-Smith | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
GB0324498D0 (en) | 2003-07-21 | 2003-11-26 | Aventis Pharma Inc | Heterocyclic compounds as P2X7 ion channel blockers |
SE0302192D0 (en) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
KR100643511B1 (en) | 2004-07-14 | 2006-11-10 | (주)아모레퍼시픽 | Hydroxamic acid derivative and the preparation method thereof |
SE0302488D0 (en) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
TWI368507B (en) | 2004-02-20 | 2012-07-21 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
KR20070115583A (en) * | 2004-06-29 | 2007-12-06 | 화이자 프로덕츠 인코포레이티드 | Method for preparing 5-[4-(2-hydroxy-ehtyl)-3,5-dioxo-4,5-dihydro-3h-[1,2,4]-triazin-2-yl]-benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid |
WO2006003500A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
WO2006003517A1 (en) * | 2004-06-29 | 2006-01-12 | Warner-Lambert Company Llc | Combination therapies utilizing benzamide inhibitors of the p2x7 receptor |
SA05260265A (en) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | Novel compounds |
EP1632491A1 (en) | 2004-08-30 | 2006-03-08 | Laboratorios Del Dr. Esteve, S.A. | Substituted indole compounds and their use as 5-HT6 receptor modulators |
US20060063834A1 (en) * | 2004-09-09 | 2006-03-23 | Frangioni John V | Substituted adamantanes, and methods of making the same |
SE0402925D0 (en) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
AU2006210572B2 (en) * | 2005-02-03 | 2011-08-04 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
EP2001474B1 (en) | 2006-03-16 | 2016-03-09 | Second Genome, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
WO2007109201A2 (en) * | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
TWI464148B (en) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
DK1937643T3 (en) | 2006-03-16 | 2016-10-10 | Second Genome Inc | Bicycloheteroarylforbindelser som p2x7-modulatorer og anvendelser deraf |
EA018036B1 (en) | 2006-11-27 | 2013-05-30 | Х. Лундбекк А/С | Heteroaryl amide derivatives |
US20100086544A1 (en) * | 2006-12-11 | 2010-04-08 | Mass Robert D | Compositions and methods for treating a neoplasm |
DK2124562T3 (en) | 2007-03-09 | 2016-08-01 | Second Genome Inc | BICYCLOHETEROARYLFORBINDELSER AS P2X7 modulators and uses thereof |
ES2388454T3 (en) | 2007-03-22 | 2012-10-15 | Astrazeneca Ab | Quinoline derivatives for the treatment of inflammatory diseases |
CA2682925A1 (en) | 2007-04-10 | 2008-10-16 | David C. Ihle | Heteroaryl amide analogues |
CL2008001933A1 (en) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Pyrimidine derived compounds, raph kinase inhibitors; intermediate compounds; preparation procedure; pharmaceutical composition; and its use to treat proliferative, cardiac, neurodegenerative, inflammatory, bone, immunological, viral disease, among others. |
JP2010532381A (en) * | 2007-06-29 | 2010-10-07 | サネシス ファーマシューティカルズ, インコーポレイテッド | Heterocyclic compounds useful as RAF kinase inhibitors |
PT2178865E (en) * | 2007-07-19 | 2015-11-16 | Lundbeck & Co As H | 5-membered heterocyclic amides and related compounds |
US10308514B2 (en) | 2007-09-07 | 2019-06-04 | Cbn Nano Technologies Inc. | Systems and methods for the manufacture of atomically-precise products |
CL2008002782A1 (en) * | 2007-09-21 | 2009-07-31 | Genentech Inc | Neutralizing anti-bv8 antibody; composition comprising it; and its use to treat tumors in humans previously treated with a vascular endothelial growth factor antagonist. |
MX2010004705A (en) | 2007-10-31 | 2010-05-27 | Nissan Chemical Ind Ltd | Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors. |
KR100899335B1 (en) * | 2007-11-27 | 2009-05-26 | (주)아모레퍼시픽 | Adamantane derivative having elastase inhibition effect and the method for preparing thereof |
PE20091036A1 (en) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | QUINOLINE DERIVATIVE AS ANTAGONIST OF THE P2X7 RECEPTOR |
US8815892B2 (en) | 2008-03-25 | 2014-08-26 | Affectis Pharmaceuticals Ag | P2X7R antagonists and their use |
PL2105164T3 (en) | 2008-03-25 | 2011-05-31 | Affectis Pharmaceuticals Ag | Novel P2X7R antagonists and their use |
PL2243772T3 (en) | 2009-04-14 | 2012-05-31 | Affectis Pharmaceuticals Ag | Novel P2X7R antagonists and their use |
EP2322149A1 (en) | 2009-11-03 | 2011-05-18 | Universidad del Pais Vasco | Methods and compositions for the treatment of ischemia |
CN102958927A (en) | 2010-05-12 | 2013-03-06 | Abbvie公司 | Indazole inhibitors of kinase |
WO2011141194A1 (en) | 2010-05-14 | 2011-11-17 | Affectis Pharmaceuticals Ag | Novel methods for the preparation of p2x7r antagonists |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
KR101957843B1 (en) * | 2011-10-06 | 2019-03-14 | (주)아모레퍼시픽 | Novel adamatan derivative compound |
CN103319493B (en) * | 2012-03-19 | 2016-02-10 | 艾琪康医药科技(上海)有限公司 | A kind of method of synthesizing 1-methylol-3-hydrogen-2-oxa-diamantane and derivative thereof |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9676677B2 (en) | 2013-02-28 | 2017-06-13 | Robert A. Freitas, JR. | Build sequences for mechanosynthesis |
US10197597B2 (en) | 2013-02-28 | 2019-02-05 | Cbn Nano Technologies Inc. | Build sequences for mechanosynthesis |
US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
WO2016032182A1 (en) * | 2014-08-29 | 2016-03-03 | (주)아모레퍼시픽 | Novel adamantane derivative compound |
KR102529578B1 (en) | 2014-08-29 | 2023-05-09 | (주)아모레퍼시픽 | Novel adamatan derivative compound |
RU2608737C1 (en) * | 2015-10-27 | 2017-01-23 | Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) | Use of adamantane-containing indoles and their hydrochlorides as cytoprotectors and for treating and preventing diseases associated with increase in cytosolic calcium concentration and pharmacological agent based thereon |
RU2608631C1 (en) * | 2015-10-27 | 2017-01-23 | Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) | Adamantane-containing indoles and their hydrochlorides with microtubules stabilizing property, methods of their production, pharmacological agent based thereon and method of treating and preventing diseases associated with microtubule system disorders |
RU2621348C1 (en) * | 2016-03-25 | 2017-06-02 | Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) | Application of adamantane indole and their hydrochlorides as cholinesterase inhibitors and nmda-receptors blockers |
US10067160B2 (en) | 2016-11-16 | 2018-09-04 | CBN Nano Technologies, Inc. | Sequential tip systems and methods for positionally controlled chemistry |
WO2018093728A1 (en) | 2016-11-16 | 2018-05-24 | Nanofactory Corporation | Systems and methods for mechanosynthesis |
CN109956973B (en) * | 2017-12-25 | 2020-11-03 | 上海启甄环境科技有限公司 | Synthetic method of radioactive isotope carbon-14 labeled Dufulin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3464998A (en) | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
US3789072A (en) * | 1970-04-22 | 1974-01-29 | Squibb & Sons Inc | Carboxamides |
CA2015473C (en) | 1989-04-28 | 1998-04-14 | Iwao Kinoshita | Triphenylmethane derivatives |
CA2091194A1 (en) | 1992-04-08 | 1993-10-09 | Richard D. Connell | 2-oxo-ethyl derivatives as immunosuppressants |
CA2167154A1 (en) | 1993-08-10 | 1995-02-16 | Sarkis Barret Kalindjian | Gastrin and cck receptor ligands |
GB9409150D0 (en) | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
-
1997
- 1997-12-05 SE SE9704545A patent/SE9704545D0/en unknown
-
1998
- 1998-12-01 IL IL13650398A patent/IL136503A0/en unknown
- 1998-12-01 AU AU17914/99A patent/AU746716B2/en not_active Ceased
- 1998-12-01 PT PT98962752T patent/PT1036058E/en unknown
- 1998-12-01 SK SK841-2000A patent/SK8412000A3/en unknown
- 1998-12-01 RU RU2000117580/04A patent/RU2197477C2/en not_active IP Right Cessation
- 1998-12-01 ES ES98962752T patent/ES2195433T3/en not_active Expired - Lifetime
- 1998-12-01 HU HU0100431A patent/HUP0100431A3/en unknown
- 1998-12-01 BR BR9813368-3A patent/BR9813368A/en not_active IP Right Cessation
- 1998-12-01 EP EP98962752A patent/EP1036058B1/en not_active Expired - Lifetime
- 1998-12-01 KR KR1020007005997A patent/KR20010032708A/en not_active Application Discontinuation
- 1998-12-01 PL PL98340890A patent/PL340890A1/en unknown
- 1998-12-01 JP JP2000524257A patent/JP2001525391A/en active Pending
- 1998-12-01 EE EEP200000320A patent/EE200000320A/en unknown
- 1998-12-01 AT AT98962752T patent/ATE234274T1/en not_active IP Right Cessation
- 1998-12-01 NZ NZ504375A patent/NZ504375A/en unknown
- 1998-12-01 US US09/230,511 patent/US6242470B1/en not_active Expired - Fee Related
- 1998-12-01 CN CN98811835A patent/CN1280560A/en active Pending
- 1998-12-01 CA CA002312889A patent/CA2312889A1/en not_active Abandoned
- 1998-12-01 DE DE69812159T patent/DE69812159T2/en not_active Expired - Fee Related
- 1998-12-01 TR TR2000/01558T patent/TR200001558T2/en unknown
- 1998-12-01 WO PCT/SE1998/002189 patent/WO1999029660A1/en not_active Application Discontinuation
- 1998-12-01 DK DK98962752T patent/DK1036058T3/en active
-
2000
- 2000-05-31 NO NO20002785A patent/NO20002785L/en not_active Application Discontinuation
- 2000-12-12 HK HK00107989A patent/HK1028594A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000117580A (en) | NEW CONNECTIONS | |
ES2154253T3 (en) | INHIBITION OF THE ACTIVITY OF P38 CINASA USING REPLACED HETEROCYCLIC UREAS. | |
RU2000117574A (en) | Derivatives Adamantans | |
RU2001132570A (en) | Urea-substituted imidazoquinolines | |
RU2005107314A (en) | Pyrimidine derivatives characterized by anti-proliferative activity | |
RU97118591A (en) | DERIVATIVES OF ACETAMIDE, METHOD FOR ITS PREPARATION AND CONTAINING ITS PHARMACEUTICAL COMPOSITIONS | |
RU2006129312A (en) | ARILANILINE DERIVATIVES AS 2 ADRENERGIC RECEPTOR AGONISTS | |
RU98108553A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROXYMIC ACID DERIVATIVES | |
RU2008144584A (en) | 4,5-DIHYDRO- [1,2,4] TRIAZOLO [4,3-F] PERIDINES AS PLK1 PROTEINKINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
RU2003115429A (en) | DERIVATIVES OF IMIDES OF INDOLYLMALIC ACID AS PROTEINKINASE C INHIBITORS | |
JPWO2019195124A5 (en) | ||
RU2003111462A (en) | SUBSTITUTED CINNAMOUS GUANIDIDES, METHOD FOR PRODUCING THEM, THEIR USE AS A MEDICINAL PRODUCT, AND ALSO CONTAINING THEIR MEDICINAL PRODUCT | |
JPWO2019144117A5 (en) | ||
RU2006113700A (en) | AMINO SUBSTITUTED ETHYLAMITO-AGONISTS OF BETA2-ADRENERGIC RECEPTORS | |
RU95115522A (en) | CONNECTION SUITABLE FOR THE TREATMENT OF CNS DISEASES, PHARMACEUTICAL COMPOSITION | |
RU2007121219A (en) | Diazacycloalkanes as Oxytocin Agonists | |
JP2018534355A (en) | PPAR agonist, compound, pharmaceutical composition and method of use thereof | |
RU2004135304A (en) | DERIVATIVES OF 2,6-CHINOLINYL AND 2,6-NAPHTHIL, METHODS FOR THEIR PRODUCTION AND THEIR APPLICATION AS VLA-4 INHIBITORS | |
EP0372940A3 (en) | Anti-inflammatory 2-furanones | |
RU2004122427A (en) | Pyrrolidin-2-ones as inhibitors of factor XA | |
RU2004117603A (en) | HETEROCYCLIC DERIVATIVES OF GLYCINAMIDE AND THEIR APPLICATION IN MEDICINE | |
RU2007133712A (en) | METHODS FOR IMPROVING THE DISTRIBUTION OF MEDICINES | |
RU2004112781A (en) | PIPERIDINE DERIVATIVES AND THEIR APPLICATION AS MODULATORS OF ACTIVITY OF CHEMOKIN RECEPTORS (IN PARTICULAR CCR5) | |
KR970074776A (en) | Substituted 2-naphthoylguanidine, preparation method thereof, use thereof as drug or diagnostic agent, and drug containing the same | |
JP2007505105A5 (en) |